Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04607772 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT04607772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 18, 2020
Completion date
December 31, 2025
Enrollment
0 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory diffuse large b-cell lymphoma